Lung Cancer Dispatch
Follow
Find tag "Pervenio"
3.6K views | +3 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Phase II Trial Shows Feasibility of Customized Adjuvant Treatment in NSCLC, but Phase III Trial Canceled Due to Unreliability of ERCC1 Readouts

Phase II Trial Shows Feasibility of Customized Adjuvant Treatment in NSCLC, but Phase III Trial Canceled Due to Unreliability of ERCC1 Readouts | Lung Cancer Dispatch | Scoop.it

"In the phase II Tailored Postsurgical Therapy in Early-Stage NSCLC (TASTE) trial (IFCT-0801), reported in the Journal of Clinical Oncology, Wislez et al examined the feasibility of customized adjuvant treatment based on EGFR mutation status and expression of ERCC1 (excision repair cross-complementation group 1), a predictor of cisplatin response, in patients with non–small cell lung cancer (NSCLC). Although the trial met its primary endpoint of ≥ 80% of patients being able to start adjuvant chemotherapy within 2 months of surgery, a phase III trial of the customized approach was cancelled due to unreliability of ERCC1 immunohistochemical readouts."


Editor's note: This trial tested whether a particular molecular testing method could be used to decide which lung cancer patients might benefit from chemotherapy after surgery to keep the cancer from returning. While the results of the trial were promising, the third phase of the trial was canceled because of some unreliability of the molecular testing method. Another method called Pervenio, already performs a similar function.

Cancer Commons's insight:

The ASCO Post  |  Mar 31, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

New Genetic Test Helps Patients Choose Best Lung Cancer Treatment

New Genetic Test Helps Patients Choose Best Lung Cancer Treatment | Lung Cancer Dispatch | Scoop.it

In September, Southern California company Life Technologies released a new test that determines the risk of recurrence for lung cancer patients. The 14-gene, $3,995 test, called Pervenio, helps doctors decide how aggressively to treat early-stage lung cancer and whether chemotherapy or other post-surgery treatments are necessary. Though not yet covered by most insurance plans, Pervenio has already proven useful for individual patients since its release.

Cancer Commons's insight:

San Francisco Chronicle | Nov 13, 2012

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Gene May Predict if Further Cancer Treatments are Needed

Gene May Predict if Further Cancer Treatments are Needed | Lung Cancer Dispatch | Scoop.it

"A new predictive tool that could help patients with breast cancer and certain lung cancers decide whether follow-up treatments are likely to help is being developed by researchers. The findings offer insight into helping patients assess treatment risk. Radiation therapy and chemotherapy that can destroy tumors also can damage surrounding healthy tissue. So with an appropriate test, patients could avoid getting additional radiation or chemotherapy treatment they may not need."


Editor's note: This study was performed in mice, so it will be several years before patients can benefit from it. However, doctors are already using molecular testing to guide treatment decisions, often for patients with advanced lung cancer. For early-stage patients, the Pervenio test can help determine whether lung cancer is likely to return after surgery, which can let doctors know to consider preventive ("adjuvant") treatments.

Cancer Commons's insight:

ScienceDaily  |  Mar 28, 2014

more...
No comment yet.